Willingness to pay for a QALY: Past, present and future

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 8, Issue 6, 2008, Pages 575-582

  Mason, Helen ^a   Baker, Rachel ^a   Donaldson, Cam ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Quality adjusted life year; Value of a prevented fatality; Willingness to pay

Indexed keywords

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FATALITY; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH SERVICE; HEALTH STATUS; INTERMETHOD COMPARISON; LIFE EXPECTANCY; LONGEVITY; MEDICAL DECISION MAKING; PATIENT SAFETY; PERSONAL VALUE; PUBLIC HEALTH; QUALITY ADJUSTED LIFE YEAR; RESOURCE ALLOCATION; REVIEW;

EID: 68649113805     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.8.6.575     Document Type: Review

References (31)

1. Johansson P-O. An Introduction to Modern Welfare Economics. Cambridge University Press, Cambridge, UK (1997).
2. Smith R, Richardson J. Can we estimate the 'social' value of a QALY? Four core issues to resolve. Health Policy 74(1), 77-84 (2005).
3. Brouwer WBF, Van Exel J, Donaldson C, Baker R. The new myth: the social value of the QALY. Pharmacoeconomics 26(1), 1-4 (2008).
4. Viscusi WK, Aldy JE. The value of a statistical life: a critical review of market estimates throughout the world. J. Risk Uncertain. 27(1), 5-76 (2003).
5. Abelson P. The value of life and health for public policy. Econ. Rec. 79, S2-S13 (2003).
6. Hirth RA, Chernew ME, Miller E, Fendrick M, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med. Decis. Making 20, 332-342 (2000).
7. Johannesson M, Meltzer D. Some reflections on cost-effectiveness analysis. Health Econ. 7(1), 1-7 (1998).
8. Mason H, Jones-Lee M, Donaldson C. Modelling the monetary value of a QALY: a new approach based on U K data. Health Econ. DOI: 10.1002/ hec.1416 (2008) (Epub ahead of print).
9. Persson U, Hjelmgren J. Halso - och sjukvarden behover kunskap om hur befolkingen varderar halsan. Lakartidningen 43, 3436-3437 (2003).
10. Fryback DG, Dasbach EJ, Klein R et al. The Beaver Dam Health Outcomes Study: initial catalogue of health-state quality factors. Med. Decis. Making 13, 89-102 (1993).
11. King JT, Tsevat J, Lave J, Roberts MS. Willingness to pay for a quality adjusted life year: implications for societal health care resource allocation. Med. Decis. Making 25(6), 667-677 (2005).
12. Blumenschein K, Johannesson M. Relationships between quality of life instruments, health states utilities and willingness to pay in patients with asthma. Ann. Allergy Asthma Immunol. 80, 189-194 (1998).
13. Cunningham SJ, Hunt NP. Relationship between utility values and willingness to pay in patients undergoing orthognathic treatment. Community Dent. Health 17, 92-96(2000).
14. Zethraeus N. Willingness to pay for hormone replacement therapy. Health Econ. 7, 31-38 (1998).
15. Olsen JA, Donaldson C. Helicopters, hearts and hips: using willingness to pay to set priorities for public sector health care programmes. Soc. Sci. Med. 46(1), 1-12 (1998).
16. Ethgen O, Tancredi A, Lejeune E, Kvasz A, Zegels B. Do utility values and willingness to pay suitably reflect health outcome in hip and knee osteoarthritis? A comparative analysis with the WOMAC index. J. Rheumatol. 30(11), 2452-2459 (2003).
17. Donaldson C, Baker R, Bateman I et al. Weighting and valuing quality adjusted life years: preliminary results from the Social Value of a QALY project. In: Report for the Methodology Programme. NIHR, Birmingham, UK (2008).
18. Gyrd-Hansen D. Willingness to pay for a QALY. Health Econ. 12, 1049-1060 (2003).
19. Johannesson M, Johansson P-O. Quality of life and the WTP for an increase in life expectancy at an advanced age. J. Public Econ.65, 219-228 (1997).
20. Johnson FR, Desvousges WH, Ruby M, Stieb D, De Civita P. Eliciting stated health preferences: an application to willingness to pay for longevity. Med. Decis. Making 18(Suppl.), S57-S67 (1998).
21. Byrne MM, O'Malley K, Suarez-Almazor ME. Willingness to pay per quality adjusted life year in a study of knee osteoarthritis. Med. Decis. Making 25(6), 655-666 (2005).
22. Olsen JA. Aiding priority setting in health care: is there a role for the contingent valuation method? Health Econ. 6, 603-612 (1997).
23. Van Houtven G, Powers J, Jessup A, Yang J-C. Valuing avoided morbidity using meta-regression analysis: what can health status measures and QALYs tell us about WTP? Health Econ. 15, 775-795 (2006).
24. Hammitt J, Liu J-T. Is there a 'cancer premium'? Harvard Center for Risk Analysis 12(2), (2004).
25. Krupnick A, Alberini A, Cropper M et al. Age, health and the willingness to pay for mortality risk reductions: a contingent valuation survey of Ontario residents. J. Risk Uncertain. 24(2), 161-186 (2002).
26. Alberini A, Cropper M, Krupnick A, Simon NB. Does the value of a statistical life vary with age and health status? Evidence from the US and Canada. J. Environ. Econ. Manage. 48, 769-792 (2004).
27. O'Dowd A. Watchdog set to reject four drugs for kidney cancer on the NHS. BMJ 337:a1262 (2008).
28. Kmietowicz Z. Professors call for review of way cancer drugs in NHS are rationed. BMJ 337, a1450 (2008).
29. House of Commons Health Committee. National Institute for Health and Clinical Excellence. House of Commons, The Stationary Office Limited, Norwich, UK (2007).
30. Culyer A, McCabe C, Briggs A et al. Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. J. Health Serv. Res. Policy 12, 56-58 (2007).
31. Bate A, Murtagh M, Donaldson C. Managing to manage scarce resources in the English NHS. What can economics teach? What can economics learn? Health Policy 84, 249-261 (2007).